# Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Canonical URL: https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-william-blair-46th-annual-growth-stock-confer-369a40b0
Ticker: RGEN
Company: Repligen
Source: Repligen
Published: 2026-05-22 11:30 EST
## Summary

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology...

## Article Body
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3 rd at 10:40 a.m. CT.

A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com , and follow us on LinkedIn .

Repligen Contact: Jacob Johnson VP, Investor Relations 781-419-0204 investors@repligen.com
## Recent Company News
- 2026-07-28 11:00 EST — [Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance](https://biopharmsignal.com/news/RGEN/repligen-reports-second-quarter-2026-financial-results-and-updates-full-year-202-465808e8) — Source: Repligen
- 2026-07-22 10:00 EST — [Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media](https://biopharmsignal.com/news/RGEN/repligen-to-acquire-biolife-solutions-expanding-its-cell-therapy-capabilities-wi-b25607c1) — Source: Repligen
- 2026-07-15 11:30 EST — [Repligen to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RGEN/repligen-to-report-second-quarter-2026-financial-results-f6af0b9d) — Source: Repligen
- 2026-05-22 11:30 EST — [Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference](https://biopharmsignal.com/news/RGEN/repligen-corporation-to-present-at-william-blair-46th-annual-growth-stock-confer-369a40b0) — Source: Repligen
- 2026-05-20 11:30 EST — [Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report](https://biopharmsignal.com/news/RGEN/repligen-announces-publication-of-the-company-s-2025-corporate-sustainability-re-9ff9ce31) — Source: Repligen
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)